Damora Therapeutics is a Waltham biopharmaceutical company developing antibody treatments for blood disorders. DMRA reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 25 | Guggenheim | Maintained | Buy | |
| Jul 30 | Wedbush | Target raised | Buy | |
| Jul 27 | Jefferies | Initiated | Buy | |
| Jun 12 | Wedbush | Reiterated | Buy | |
| Jun 11 | HC Wainwright & Co. | Initiated | Buy |
Seasonality
How DMRA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in DMRA in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DMRA is in one of them and how their past DMRA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered DMRA in an article yet. Here's the latest on the wider market.
About Damora Therapeutics
Damora Therapeutics is a biopharmaceutical company based in Waltham, Massachusetts, that develops treatments for blood disorders. Its lead candidate, DMR-001, is an antibody designed to target mutant calreticulin, a protein that drives essential thrombocythemia and myelofibrosis, two myeloproliferative neoplasms that affect the bone marrow. The company is also developing two related candidates for the same group of disorders. Its intended patients are people living with these conditions, and none of its candidates are on the market yet.
- Headquarters
- Waltham, MA